Natera, Inc. NTRA

Company Overview

Natera, Inc. is a U.S.-based molecular diagnostics company focused on cell-free DNA and genetic testing technologies across the oncology, women’s health, and organ health markets. The company develops and commercializes proprietary blood- and tissue-based diagnostic tests that are primarily used for cancer detection and monitoring, prenatal screening, and transplant rejection assessment. Natera operates within the broader healthcare diagnostics and precision medicine industries, with revenue primarily generated from clinical testing services reimbursed by commercial insurers, government healthcare programs, and healthcare providers.

Natera’s principal commercial offerings include the Signatera molecular residual disease (MRD) test for oncology, the Panorama non-invasive prenatal test (NIPT), and the Prospera transplant assessment test. The company has positioned itself around personalized diagnostics enabled by next-generation sequencing and bioinformatics capabilities, particularly through tumor-informed oncology testing and cell-free DNA analysis. Originally founded in 2004 as Gene Security Network, the company initially focused on reproductive genetics before expanding into oncology and organ health. It later rebranded as Natera and has since broadened its platform through internal development, clinical collaborations, and expanded reimbursement coverage.